IR Insights: Recapping our Collaboration with Recordati to Globally Commercialize our Investigational Propionic Acidemia Therapy
Earlier today, Moderna announced a strategic collaboration with Recordati to advance Moderna’s investigational propionic acidemia (PA) therapy, mRNA-3927, through the final stages of clinical development and, upon approval, global commercialization.
Stéphane Bancel, CEO, sat down for an episode of IR Insights to give an overview of the partnership. Watch the episode here:
Forward-Looking Statements
This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s collaboration with Recordati to globally commercialize mRNA-3927; Moderna’s clinical development and manufacturing of mRNA-3927; the potential for regulatory approval and commercialization of mRNA-3927; anticipated initiation of a registrational study for mRNA-3705; and potential future partnerships to advance additional rare disease programs. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this post.